Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast CancerHeikki Joensuu, Henrik Lindman, Paul Nyandoto et al.|JAMA Oncology|2018Cited by 149
LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancerHelena Earl, Xavier Pivot, Louise Hiller et al.|Annals of Oncology|2021Cited by 25
Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for <i>ERBB2</i>-Positive Breast CancerHeikki Joensuu, Henrik Lindman, Judith Fraser et al.|JAMA Network Open|2024Cited by 2